Content
01/30/2025 Melbourne Australia
Diag-Nose.io completed $2 million Seed Round funding. Investors include Breakthrough Victoria (lead), Radar Ventures.
#Biotech  
About
Diag-Nose.io, founded in 2020, is a biotechnology company focused on translating the complexities of the unified airway into precision diagnostic and drug discovery solutions. Their precision medicine technology combines advanced proteomics, computational biology, and AI (machine learning) to create a scalable respiratory biology model. This innovation aims to help clinicians prescribe the right treatments faster and enable researchers to accelerate the development of new therapies. The company’s flagship platform, RhinoMAP™, leverages proteomic data to predict respiratory disease activity, monitor therapy response and predict treatment efficacy in advance, with an initial focus on anti-Th2 biologics.
Startup
Diag-Nose.io
https://diag-nose.io Claim Profile
Location:
Melbourne Australia
Sector:
Biotech
Download StockFan App Ad
Stock market data, news and community, all integrated.
Features include real time stock quotes, interactive charts, technical signals, institutional & insider ownerships, stock screener, ETF rankings, SEC filings, press releases, videos, earnings calendar, social media posts, group chats.